News coverage about Grifols SA, Barcelona (NASDAQ:GRFS) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Grifols SA, Barcelona earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.517351437297 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- FACTBOX-Companies with big business operations in Catalonia (cnbc.com)
- Grifols, SA (GRFS) has a value of $21.45 per share While Alcobra Ltd. (ADHD) is stand at $1.01 – Stocks Gallery (stocksgallery.com)
- Healthcare Stock Buy Signal: Grifols, SA (GRFS) – Street Observer (press release) (streetobserver.com)
- Grifols, S.A. (GRFS) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
- Consensus score reveals Buy position in Stocks: Grifols, SA (GRFS) ,Humana Inc. (HUM) – Street Observer (press release) (streetobserver.com)
GRFS has been the subject of a number of analyst reports. BidaskClub raised Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Goldman Sachs Group, Inc. (The) downgraded Grifols SA, Barcelona from a “buy” rating to a “neutral” rating in a research note on Friday, June 30th. Bank of America Corporation reaffirmed a “buy” rating on shares of Grifols SA, Barcelona in a research note on Tuesday, July 4th. Finally, Zacks Investment Research raised Grifols SA, Barcelona from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research note on Tuesday, July 4th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $24.00.
Grifols SA, Barcelona (NASDAQ:GRFS) opened at 21.12 on Friday. The firm has a market cap of $28.86 billion, a P/E ratio of 42.97 and a beta of 0.98. Grifols SA, Barcelona has a 1-year low of $14.27 and a 1-year high of $22.83. The company has a 50-day moving average price of $20.93 and a 200-day moving average price of $20.69.
WARNING: This report was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://transcriptdaily.com/2017/10/08/grifols-sa-barcelona-grfs-earning-somewhat-favorable-media-coverage-analysis-shows.html.
About Grifols SA, Barcelona
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.